1. Home
  2. EVCM vs ZLAB Comparison

EVCM vs ZLAB Comparison

Compare EVCM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVCM
  • ZLAB
  • Stock Information
  • Founded
  • EVCM 2006
  • ZLAB 2013
  • Country
  • EVCM United States
  • ZLAB China
  • Employees
  • EVCM N/A
  • ZLAB N/A
  • Industry
  • EVCM EDP Services
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVCM Technology
  • ZLAB Health Care
  • Exchange
  • EVCM Nasdaq
  • ZLAB Nasdaq
  • Market Cap
  • EVCM 2.0B
  • ZLAB 1.8B
  • IPO Year
  • EVCM 2021
  • ZLAB 2017
  • Fundamental
  • Price
  • EVCM $10.75
  • ZLAB $31.24
  • Analyst Decision
  • EVCM Buy
  • ZLAB Strong Buy
  • Analyst Count
  • EVCM 11
  • ZLAB 4
  • Target Price
  • EVCM $11.45
  • ZLAB $52.50
  • AVG Volume (30 Days)
  • EVCM 68.3K
  • ZLAB 976.3K
  • Earning Date
  • EVCM 11-12-2024
  • ZLAB 11-12-2024
  • Dividend Yield
  • EVCM N/A
  • ZLAB N/A
  • EPS Growth
  • EVCM N/A
  • ZLAB N/A
  • EPS
  • EVCM N/A
  • ZLAB N/A
  • Revenue
  • EVCM $691,687,000.00
  • ZLAB $322,711,000.00
  • Revenue This Year
  • EVCM $4.47
  • ZLAB $48.34
  • Revenue Next Year
  • EVCM $5.08
  • ZLAB $47.12
  • P/E Ratio
  • EVCM N/A
  • ZLAB N/A
  • Revenue Growth
  • EVCM 6.23
  • ZLAB 28.16
  • 52 Week Low
  • EVCM $6.22
  • ZLAB $13.48
  • 52 Week High
  • EVCM $12.35
  • ZLAB $36.60
  • Technical
  • Relative Strength Index (RSI)
  • EVCM 60.86
  • ZLAB 70.41
  • Support Level
  • EVCM $10.42
  • ZLAB $31.52
  • Resistance Level
  • EVCM $10.90
  • ZLAB $36.60
  • Average True Range (ATR)
  • EVCM 0.19
  • ZLAB 1.36
  • MACD
  • EVCM 0.04
  • ZLAB 0.34
  • Stochastic Oscillator
  • EVCM 88.61
  • ZLAB 58.60

About EVCM EverCommerce Inc.

EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts..

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Share on Social Networks: